GlobalData on MSN12d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Zacks.com on MSN12d
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...
Nasdaq13d
Intellia Therapeutics Doses First Patient in Global Phase 3 Study of NTLA-2002 for Hereditary Angioedema Treatment
Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...
Nasdaq26d
Intellia Therapeutics Announces Strategic Priorities and Milestones for NTLA-2002 and Nexiguran Ziclumeran in 2025
Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...
Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Un hito para las terapias de edición genética
Ronald Palacios Castrillo ¿Las terapias de edición genética realmente ayudan a los pacientes? Aunque ha habido un considerable entusiasmo sobre la perspectiva de administrar directamente una terapia d ...